Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level (iFIT)

9 giugno 2026 aggiornato da: University of Leeds

iFIT (UK-MRA Myeloma XVIII): Immunotherapy Approaches Adapted for Fitness in Newly Diagnosed Transplant Ineligible Patients With Myeloma

iFIT is a trial for newly diagnosed transplant-ineligible patients with the bone marrow cancer myeloma. These patients are generally older and have a lower level of fitness than others. Patients can take part if their doctor would otherwise recommend the standard NHS treatment daratumumab, lenalidomide and dexamethasone (DRd). After six months of DRd, the subsequent treatment a patient receives in iFIT is based on two factors: the patient's fitness level and treatment response. The trial compares different treatment strategies to determine whether outcomes can be improved for specific patient groups.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

1226

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

  • Regno Unito
      • Bristol, Regno Unito, BS2 8ED
      • Eastbourne, Regno Unito, BN21 2UD
      • Leeds, Regno Unito, LS9 7TF
      • London, Regno Unito, SM2 5PT

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Descrizione

Eligibility criteria for registration:

Inclusion criteria for registration:

  1. Newly diagnosed as having symptomatic MM, plasma cell leukaemia or non-secretory MM according to IMWG diagnostic criteria 2014.
  2. Considered not suitable to receive autologous stem cell transplant as part of their first line therapy by the treating clinician,
  3. Planned for treatment with Daratumumab, Lenalidomide and dexamethasone (DRd) as first line therapy as standard of care,
  4. Aged 18 years or greater,
  5. Able to provide full informed consent, and
  6. Prepared to comply with pregnancy prevention plan.

Exclusion criteria for registration:

  1. Smouldering myeloma (SMM), primary amyloidosis, solitary plasmacytoma of bone or extramedullary plasmacytoma (without additional evidence of myeloma),
  2. Pregnant, breastfeeding, plans to become pregnant, or plans to father a child whilst enrolled in the study or within 3 months after the last dose,
  3. Previous treatment for myeloma, except as specified in the protocol,
  4. Active systemic viral, fungal or bacterial infection requiring systemic therapy. Criteria for specific chronic infections clarified in the protocol, or
  5. Participation in any other interventional study for myeloma that involves an IMP during treatment and active monitoring.

Additional eligibility criteria for randomisation into iFIT1/iFIT2/iFIT3 pathways, as follows:

Inclusion criteria for randomisation into all iFIT1/iFIT2/iFIT3 pathways:

  • Completed 6 cycles of DRd induction therapy after registering within the iFIT study,
  • Able to provide full informed consent, and
  • Prepared to comply with pregnancy prevention plan.

Inclusion criteria specific to randomisation pathways:

  • Dexamethasone may have been stopped due to toxicity and the participant will remain eligible (iFIT1 and iFIT3),
  • Planned to continue on at least daratumumab (monthly) and lenalidomide (at any dose level) (iFIT1 and iFIT3),
  • Planned to continue on all three DRd medications (dose reductions are allowed) (iFIT2),
  • Achieved a partial response (PR) biochemically (irrespective of MRD status) or achieved a ≥VGPR and are MRD positive, as confirmed by HMDS (central laboratory) (iFIT1 and iFIT2),
  • Achieved a ≥VGPR and are MRD negative, as confirmed by HMDS (central laboratory) (iFIT3),
  • Categorised as FIT or UNFIT according to the IMWG frailty index (iFIT1),
  • Categorised as FRAIL according to the IMWG frailty index (iFIT2), and
  • Meet the blood criteria specified in the protocol within 14 days before randomisation (haematological and biochemical) (iFIT1).

Exclusion criteria for randomisation into all iFIT1/iFIT2/iFIT3 pathways:

  • Received systemic anti-myeloma therapy other than DRd prior to randomisation. Steroids given (by any route) for reasons other than myeloma disease control are allowed,
  • Received a stem cell transplant,
  • Participation in any other interventional study for myeloma that involves an IMP during treatment and active monitoring, and
  • Pregnant, breast feeding, plans to become pregnant, or plans to father a child whilst enrolled in the study or within a specified period after the last dose.

Exclusion criteria specific to randomisation pathways:

  • Stable disease (SD) or progressive disease (PD) as per IMWG response criteria (iFIT1 and iFIT2),
  • Partial response (PR), stable disease (SD) or progressive disease (PD) as per IMWG response criteria (iFIT3), and
  • Further exclusion criteria related to safety of interventions (iFIT1).

Full inclusion and exclusion criteria are listed in the protocol.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: DRd induction
All participants will receive standard of care treatment with daratumumab, lenalidomide, and dexamethasone for an initial 6 cycles.
Droga: Daratumumab
Participants will receive daratumumab by subcutaneous injection. Each cycle is 28 days.
Altri nomi:
  • D
  • Dara
Droga: Lenalidomide
Taken orally as capsules. Each cycle is 28 days. Dose can be adjusted for frailty and renal function.
Altri nomi:
  • Revimid
  • R
Droga: Dexamethasone
Taken as oral tablets, oral solution, or given by IV. Each cycle is 28 days. Dose can be adjusted for frailty and renal function.
Altri nomi:
  • D
Comparatore attivo: iFIT1 - DRd to PD
Participants assigned to the iFIT1 pathway and randomised to this arm will continue standard of care treatment with daratumumab, lenalidomide, and dexamethasone until progressive disease. Dexamethasone may be stopped due to toxicity.
Droga: Daratumumab
Participants will receive daratumumab by subcutaneous injection. Each cycle is 28 days.
Altri nomi:
  • D
  • Dara
Droga: Lenalidomide
Taken orally as capsules. Each cycle is 28 days. Dose can be adjusted for frailty and renal function.
Altri nomi:
  • Revimid
  • R
Droga: Dexamethasone
Taken as oral tablets, oral solution, or given by IV. Each cycle is 28 days. Dose can be adjusted for frailty and renal function.
Altri nomi:
  • D
Sperimentale: iFIT1 - Daratumumab plus teclistamab (Dara-Tec)
Participants assigned to the iFIT1 pathway and randomised to this arm will receive treatment with daratumumab and teclistamab for a fixed duration and then be actively monitored until progressive disease.
Droga: Daratumumab
Participants will receive daratumumab by subcutaneous injection. Each cycle is 28 days.
Altri nomi:
  • D
  • Dara
Droga: Teclistamab
Participants will receive teclistamab by subcutaneous injection. Each cycle is 28 days.
Altri nomi:
  • Tec
Sperimentale: iFIT1 - Daratumumab plus talquetamab (Dara-Tal)
Participants assigned to the iFIT1 pathway and randomised to this arm will receive treatment with daratumumab and talquetamab for a fixed duration and then be actively monitored until progressive disease.
Droga: Daratumumab
Participants will receive daratumumab by subcutaneous injection. Each cycle is 28 days.
Altri nomi:
  • D
  • Dara
Droga: Talquetamab
Participants will receive talquetamab by subcutaneous injection. Each cycle is 28 days.
Altri nomi:
  • Tal
Comparatore attivo: iFIT2 - DRd to PD
Participants assigned to the iFIT2 pathway and randomised to this arm will continue standard of care treatment with daratumumab, lenalidomide, and dexamethasone until progressive disease.
Droga: Daratumumab
Participants will receive daratumumab by subcutaneous injection. Each cycle is 28 days.
Altri nomi:
  • D
  • Dara
Droga: Lenalidomide
Taken orally as capsules. Each cycle is 28 days. Dose can be adjusted for frailty and renal function.
Altri nomi:
  • Revimid
  • R
Droga: Dexamethasone
Taken as oral tablets, oral solution, or given by IV. Each cycle is 28 days. Dose can be adjusted for frailty and renal function.
Altri nomi:
  • D
Sperimentale: iFIT2 - DR to PD
Participants assigned to the iFIT2 pathway and randomised to this arm will continue treatment with daratumumab and lenalidomide until progressive disease.
Droga: Daratumumab
Participants will receive daratumumab by subcutaneous injection. Each cycle is 28 days.
Altri nomi:
  • D
  • Dara
Droga: Lenalidomide
Taken orally as capsules. Each cycle is 28 days. Dose can be adjusted for frailty and renal function.
Altri nomi:
  • Revimid
  • R
Comparatore attivo: iFIT3 - DR to PD
Participants assigned to the iFIT3 pathway and randomised to this arm will continue treatment with daratumumab and lenalidomide until progressive disease.
Droga: Daratumumab
Participants will receive daratumumab by subcutaneous injection. Each cycle is 28 days.
Altri nomi:
  • D
  • Dara
Droga: Lenalidomide
Taken orally as capsules. Each cycle is 28 days. Dose can be adjusted for frailty and renal function.
Altri nomi:
  • Revimid
  • R
Sperimentale: iFIT3 - DR for 18 cycles
Participants assigned to the iFIT3 pathway and randomised to this arm will continue treatment with daratumumab and lenalidomide for 18 cycles, and then be actively monitored until progressive disease.
Droga: Daratumumab
Participants will receive daratumumab by subcutaneous injection. Each cycle is 28 days.
Altri nomi:
  • D
  • Dara
Droga: Lenalidomide
Taken orally as capsules. Each cycle is 28 days. Dose can be adjusted for frailty and renal function.
Altri nomi:
  • Revimid
  • R

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
iFIT1: Progression-free survival (PFS)
Lasso di tempo: From iFIT1 randomisation to PFS event, assessed up to a maximum of 10.5 years post-randomisation.
The time from iFIT1 randomisation to progression or death from any cause. Participants alive and progression-free at the time of analysis will be censored at their last known date to be alive and progression-free.
From iFIT1 randomisation to PFS event, assessed up to a maximum of 10.5 years post-randomisation.
iFIT2: Event-free survival (EFS)
Lasso di tempo: From iFIT2 randomisation to EFS event, assessed up to a maximum of 6.5 years post-randomisation.
The time from iFIT2 randomisation to the first of the following events: grade 4 haematological AEs, grade 3 and 4 non-haematological AEs (including SPMs), discontinuation of trial treatment, progression or death. Participants event-free at the time of analysis will be censored at their last date known to be alive and event-free.
From iFIT2 randomisation to EFS event, assessed up to a maximum of 6.5 years post-randomisation.
iFIT3: Progression-free survival (PFS) and participant-reported overall health and quality of life (QoL) - co-primary outcomes
Lasso di tempo: PFS: from iFIT3 randomisation to PFS event, assessed up to a maximum of 10.5 years post-randomisation. QoL: measured at the start of cycle 1 and after 6 28-day cycles of DRd induction, and further timepoints up to 30 months post-iFIT3 randomisation.

PFS: The time from iFIT3 randomisation to progression or death from any cause. Participants alive and progression-free at the time of analysis will be censored at their last known date to be alive and progression-free.

QoL: The GHS/QoL scale score of the EORTC QLQ-C30 questionnaire. The QoL primary endpoint is measured at 30 months (2.5 years) after iFIT3 randomisation.
PFS: from iFIT3 randomisation to PFS event, assessed up to a maximum of 10.5 years post-randomisation. QoL: measured at the start of cycle 1 and after 6 28-day cycles of DRd induction, and further timepoints up to 30 months post-iFIT3 randomisation.

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Progression-free survival (PFS; iFIT2 only)
Lasso di tempo: From iFIT2 randomisation to PFS event, assessed up to a maximum of 10.5 years post-randomisation.
The time from iFIT2 randomisation to progression or death from any cause. Participants alive and progression-free at the time of analysis will be censored at their last known date to be alive and progression-free.
From iFIT2 randomisation to PFS event, assessed up to a maximum of 10.5 years post-randomisation.
Time to progression (TTP)
Lasso di tempo: From iFIT1/iFIT2/iFIT3 randomisation to TTP event, assessed up to a maximum of 10.5 years post-randomisation.
The time from iFIT1/iFIT2/iFIT3 randomisation to first documented evidence of disease progression. Participants who died without progression will be censored at their date of death. Participants alive and progression-free at the time of analysis will be censored at their last known date to be alive and progression-free.
From iFIT1/iFIT2/iFIT3 randomisation to TTP event, assessed up to a maximum of 10.5 years post-randomisation.
Time to second PFS event (PFS2)
Lasso di tempo: From iFIT1/iFIT2/iFIT3 randomisation to PFS2 event, assessed up to a maximum of 10.5 years post-randomisation.
The time from iFIT1/iFIT2/iFIT3 randomisation to the second documented evidence of progressive disease or death from any cause. Participants alive and for whom a second progression has not been observed at the time of analysis will be censored at their last known date to be alive and second progression-free.
From iFIT1/iFIT2/iFIT3 randomisation to PFS2 event, assessed up to a maximum of 10.5 years post-randomisation.
Overall survival (OS)
Lasso di tempo: From iFIT1/iFIT2/iFIT3 randomisation to OS event, assessed up to a maximum of 10.5 years post-randomisation.
The time from iFIT1/iFIT2/iFIT3 randomisation to death from any cause. Participants alive at the time of analysis will be censored at their last known date to be alive.
From iFIT1/iFIT2/iFIT3 randomisation to OS event, assessed up to a maximum of 10.5 years post-randomisation.
Event-free survival (EFS; iFIT1 only)
Lasso di tempo: From iFIT1 randomisation to EFS event, assessed up to a maximum of 6.5 years post-randomisation.
The time from iFIT1 randomisation to the first of the following events: grade 4 haematological AEs (anaemia, neutropenia, thrombocytopenia), grade 3 and 4 non-haematological AEs (including SPMs), discontinuation of trial treatment, progression, or death. Participants event-free at the time of analysis will be censored at their last date known to be alive and event-free.
From iFIT1 randomisation to EFS event, assessed up to a maximum of 6.5 years post-randomisation.
Survival after progression
Lasso di tempo: From disease progression to death, assessed up to a maximum of 10.5 years post-randomisation.
The time from first documented evidence of disease progression to death from any cause. Participants alive at the time of analysis will be censored at their last known date to be alive. This endpoint is only defined for those who experience progression.
From disease progression to death, assessed up to a maximum of 10.5 years post-randomisation.
Time to next treatment (TTNT)
Lasso di tempo: From registration to TTNT event, assessed up to a maximum of 10.5 years post-randomisation.
The time from registration to the date of commencement of next treatment. Participants who do not receive next line treatment will be censored at the date of the last assessment or follow-up visit where they are known to have received no new therapy.
From registration to TTNT event, assessed up to a maximum of 10.5 years post-randomisation.
Overall response rate (ORR)
Lasso di tempo: Measured after 6 28-day cycles of standard of care induction DRd treatment, and further timepoints up to approximately 30 months post-iFIT1/iFIT2/iFIT3 randomisation, dependent on treatment pathway.
Overall response rate using the disease response category (sCR, CR, VGPR, PR, MR, SD, or PD).
Measured after 6 28-day cycles of standard of care induction DRd treatment, and further timepoints up to approximately 30 months post-iFIT1/iFIT2/iFIT3 randomisation, dependent on treatment pathway.
Attainment of ≥VGPR
Lasso di tempo: Measured after 6 28-day cycles of standard of care induction DRd treatment, and further timepoints up to approximately 30 months post-iFIT1/iFIT2/iFIT3 randomisation, dependent on treatment pathway.
Attainment of ≥VGPR using the binary disease response category (≥VGPR: sCR, CR, VGPR vs. <VGPR: PR, MR, SD, PD).
Measured after 6 28-day cycles of standard of care induction DRd treatment, and further timepoints up to approximately 30 months post-iFIT1/iFIT2/iFIT3 randomisation, dependent on treatment pathway.
Attainment of MRD negativity
Lasso di tempo: Measured after 6 28-day cycles of standard of care induction DRd treatment, and further timepoints up to approximately 30 months post-iFIT1/iFIT2/iFIT3 randomisation, dependent on treatment pathway.
Attainment of MRD negativity using the binary MRD status category (negative vs. positive) measured using flow cytometry. MRD negativity is defined as at least a serological VGPR and MRD negative bone marrow aspirate at the 10^-5 threshold.
Measured after 6 28-day cycles of standard of care induction DRd treatment, and further timepoints up to approximately 30 months post-iFIT1/iFIT2/iFIT3 randomisation, dependent on treatment pathway.
Maximum response
Lasso di tempo: From iFIT1/iFIT2/iFIT3 randomisation up to a maximum of 6.5 years post-randomisation.
The maximum response attained.
From iFIT1/iFIT2/iFIT3 randomisation up to a maximum of 6.5 years post-randomisation.
Time to improved response
Lasso di tempo: From iFIT1/iFIT2/iFIT3 randomisation to first recorded improved response, up to a maximum of 6.5 years post-randomisation.
The time from iFIT1/iFIT2/iFIT3 randomisation to first recorded improved response, where the baseline response is that recorded at the start of randomised treatment (iFIT1/iFIT2/iFIT3 cycle 1, day 1). Participants whose disease progresses or who die before an improved response is recorded will be censored at the time of progression or death, respectively. Participants alive with no improved response recorded at the time of analysis will be censored at their last known date to be alive.
From iFIT1/iFIT2/iFIT3 randomisation to first recorded improved response, up to a maximum of 6.5 years post-randomisation.
Treatment compliance
Lasso di tempo: From registration to the end of trial treatment, up to a maximum of 7 years post-registration.
Treatment compliance including whether all cycles of treatment were completed, the number of cycles completed, the total dose of each trial medication received, the number and causes of dose omissions, dose delays, and dose reductions.
From registration to the end of trial treatment, up to a maximum of 7 years post-registration.
Toxicity and safety as graded by NCI-CTCAE v5
Lasso di tempo: From registration up to a maximum of 11 years post-registration. SAEs may be reported up to 60 days post-last dose of protocol treatment/cycle of active monitoring.
Toxicity and safety based on the adverse events reported as graded by NCI-CTCAE v5. Pregnancies will also be reported.
From registration up to a maximum of 11 years post-registration. SAEs may be reported up to 60 days post-last dose of protocol treatment/cycle of active monitoring.
Incidence of secondary primary malignancies
Lasso di tempo: Measured during standard of care induction DRd treatment and following iFIT1/ iFIT2/iFIT3 randomisation, up to a maximum of 11 years post-registration.
The number and details of all other cancers, defined as secondary primary malignancies.
Measured during standard of care induction DRd treatment and following iFIT1/ iFIT2/iFIT3 randomisation, up to a maximum of 11 years post-registration.
Incidence, rate, and type of infections as graded by NCI-CTCAE v5
Lasso di tempo: Measured during standard of care induction DRd treatment and following iFIT1/iFIT2/iFIT3 randomisation, up to a maximum of 7 years post-registration.
Measured using the proportion of participants experiencing an infection of any type or grade as graded by NCI-CTCAE v5.
Measured during standard of care induction DRd treatment and following iFIT1/iFIT2/iFIT3 randomisation, up to a maximum of 7 years post-registration.
Quality of life using questionnaires
Lasso di tempo: Measured at the start of cycle 1 and after 6 28-day cycles of DRd induction, and timepoints up to 30 months post-randomisation. The IL414 is measured at the induction timepoints and in iFIT1, and the STTA after 6 28-day cycles of induction and in iFIT1.
Measured using the EQ-5D-5L, EORTC QLQ-C30, EORTC QLQ-IL413 questionnaires. This will also be measured using the EORTC QLQ IL414 questionnaire and the Scale of Subjective Total Taste Acuity (STTA) at specified timepoints only.
Measured at the start of cycle 1 and after 6 28-day cycles of DRd induction, and timepoints up to 30 months post-randomisation. The IL414 is measured at the induction timepoints and in iFIT1, and the STTA after 6 28-day cycles of induction and in iFIT1.
Objective measures of function
Lasso di tempo: Measured at the start of cycle 1, after 3 28-day cycles, and after 6 28-day cycles of standard of care induction DRd.
Measured using the 4 metre walk test and mini-cog assessments.
Measured at the start of cycle 1, after 3 28-day cycles, and after 6 28-day cycles of standard of care induction DRd.
Cost-utility
Lasso di tempo: Measured at the start of cycle 1 of DRd induction, after 6 28-day cycles of DRd induction, and further timepoints up to 30 months post-iFIT1/iFIT2/iFIT3 randomisation.
Measured using costs, QALYs and net health benefit (QALYs below £20,000).
Measured at the start of cycle 1 of DRd induction, after 6 28-day cycles of DRd induction, and further timepoints up to 30 months post-iFIT1/iFIT2/iFIT3 randomisation.

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Exploratory endpoint - investigation into bone disease and therapy
Lasso di tempo: From registration up to a maximum of 7 years post-registration.
Observe and understand current UK bone therapy practice and investigate how it impacts on various bone and clinical myeloma outcomes, in order to generate hypotheses to inform future research in this area. This includes bone therapy planned and prescribed, dental assessment received, and bone disease (including SREs) experienced.
From registration up to a maximum of 7 years post-registration.
Exploratory endpoint - infection interactions and infection risk (iFIT1 only)
Lasso di tempo: From iFIT1 randomisation up to a maximum of 6.5 years post-randomisation.
Certain genetic characteristics and medical history are suspected to influence the incidence and rate of infections. These will be investigated under this endpoint including iVIG usage and vaccination history. The ability to predict prospectively which participants are most at risk of infections could support the implementation of novel immunotherapies in practice. This will also be investigated under this endpoint.
From iFIT1 randomisation up to a maximum of 6.5 years post-randomisation.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

University of Leeds

Collaboratori

Johnson & Johnson
Cancer Research UK
Blood Cancer UK

Investigatori

  • Cattedra di studio: Gordon Cook, Leeds Institute of Clinical Trials Research
  • Cattedra di studio: Charlotte Pawlyn, Institute of Cancer Research, United Kingdom

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 giugno 2026

Completamento primario (Stimato)

1 maggio 2033

Completamento dello studio (Stimato)

1 maggio 2037

Date di iscrizione allo studio

Primo inviato

2 giugno 2026

Primo inviato che soddisfa i criteri di controllo qualità

9 giugno 2026

Primo Inserito (Effettivo)

16 giugno 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

16 giugno 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

9 giugno 2026

Ultimo verificato

1 maggio 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • 1010810

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

De-identified individual participant data datasets generated and/or analysed during the current study will be available upon request from the Clinical Trials Research Unit, University of Leeds (contact CTRU-DataAccess@leeds.ac.uk in the first instance).

The conditions of release for aggregate data may differ from those applying to individual participant data. Requests for aggregate data should also be sent to the above email address to discuss and agree suitable requirements for release.

Periodo di condivisione IPD

Data will be made available at the end of the trial, i.e. usually when all primary and secondary endpoints have been met and all key analyses are complete. Data will remain available from then on for as long as CTRU retains the data.

Criteri di accesso alla condivisione IPD

Data will be released for legitimate secondary research purposes, where the Chief Investigators, Sponsor and CTRU agree that the proposed use has scientific value and will be carried out to a high standard (scientific rigour and information governance and security), and that suitable resources are available. Data will be released in line with participants' consent, all applicable laws relating to data protection and confidentiality, and any contractual obligations to which the CTRU is subject. No IPD will be released before an appropriate agreement is in place governing data retention, usually stipulating that data recipients must delete their copy of the data at the end of the project.

The CTRU believes it is best practice for researchers who generated datasets to be involved in subsequent uses of those datasets. Recipients of trial data for secondary research will also receive data dictionaries, key trial documents and any other information required to reuse the datasets.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA
  • ICF

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Mieloma multiplo (MM)

Prove cliniche su Daratumumab

Cerca prove simili

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

CROs by country

CROs in Dominican Republic

Condizioni

Malattie rare

Interventi farmacologici

Supplementi dietetici

Sponsor / Collaboratori

Sedi

Sottoscrivi